Record Full-Year Financial Performance
Net sales of $419 million in 2025, representing 20% year-over-year growth; full-year adjusted EBITDA of nearly $106 million (approximately 25% adjusted EBITDA margin); GAAP net income of $49 million.
MiMedx Group
· MDXG
February 25th, 2026
Summary
- Earnings Call Date:
- 2026-02-25
- Change Since:
- -27.46%
- Next Earnings Date:
- 2026-08-04
Earnings Call Sentiment
NeutralThe call highlights a strong 2025 with record revenue, margin expansion and a fortified balance sheet, plus clear growth momentum and product/clinical progress in the Surgical segment. However, substantial near-term headwinds in the Wound Care market — driven by Medicare reimbursement changes, pricing disruption, prior-authorization delays and uncertainty around market sizing — lead management to guide to a lower revenue and margin profile for 2026. The company emphasizes confidence in its long-term positioning and expects recovery and above-market growth by 2027, but acknowledges a noisy transition year ahead.
Company Guidance
The company guided 2026 revenue to $340–$360 million, with Q1 expected to be the weakest quarter and “substantial” sequential increases each quarter as the market resets, and full‑year adjusted EBITDA targeted in the mid‑ to high‑teens (percent). For 2026 they expect gross margin in the mid‑ to upper‑70s, sales & marketing spending around ~50% of net sales, GAAP G&A and R&D to be flat in absolute dollars versus 2025, and a long‑term non‑GAAP effective tax rate of ~25%. Management reiterated a longer‑term view of returning to double‑digit, above‑market top‑line growth and a mid‑20s EBITDA margin by 2027 with revenue back over $400M, noted year‑end 2025 net cash of $148M (FY2025: $419M revenue and ~ $106M adjusted EBITDA), and that the Board authorized up to $100M in share repurchases over the next two years.
Strong Fourth Quarter Results
Q4 2025 net sales of $118 million, up 27% year-over-year; Wound sales $79 million (+28% YoY) and Surgical sales $39 million (+25% YoY); Q4 adjusted gross profit margin 86%; Q4 adjusted EBITDA $29 million (25% of net sales); Q4 GAAP net income $15 million ($0.10/share) and adjusted net income $20 million ($0.14/share).
Robust Balance Sheet and Cash Generation
Net cash balance of $148 million at year-end (up $24 million sequentially and ~$63 million year-over-year); Q4 free cash flow of $25 million; Board authorized share repurchase program up to $100 million over two years, providing capital flexibility.
Surgical Business Momentum and Growth
Surgical segment grew ~20% for full year 2025 and 25% in Q4; management expects continued momentum and a Surgical run-rate approaching ~$200 million by year-end as commercial investments and new product introductions scale.
Pipeline and Clinical Progress
EPIEFFECT randomized controlled trial nearly fully enrolled with a readout expected in a few months; committed to an RCT for CHORIOFIX; recent peer-reviewed publication (Journal of Inflammation) supporting immunomodulatory properties of DHACM/LHACM allografts.
Product Expansion and Strategic Partnerships
Launched AMNIOFIX Thyroid Shield; licensed three 510(k)-cleared complementary surgical products (NovaForm Wound Matrix, G4Derm Plus, Hydrelix Collagen Matrix); entered a distribution agreement for RegenKit Wound Gel (PRP) to broaden wound modality offerings.
Improved Gross Margin Driven by Product Mix
GAAP gross margin improved to ~84% in Q4 (from 82% prior year); non-GAAP adjusted gross margin was 86% in Q4, up ~200 basis points YoY, driven primarily by favorable product mix.
Operator
Good afternoon, and thank you for standing by. Welcome to the MiMedx Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Matt Notarianni, Head of Investor Relations from MiMedx. Thank you, Matt. You may begin.
Matthew Notarianni
Thank you, operator, and good afternoon, everyone. Welcome to the MiMedx Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call. With me on today's call are Chief Executive Officer, Joe Capper; and Chief Financial Officer, Doug Rice. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at mimedx.com. Joe will kick us off with some opening remarks and a summary of our operating highlights as well as a discussion of the market environment and our financial goals. Next, Doug will provide a review of our financial results for the quarter and full year. Joe will then conclude before we make ourselves available for your questions.
Before we begin, I would like to remind you that our comments today will include forward-looking statements, including statements regarding future sales, operating results and cash balance growth, future margins and expenses, our product portfolios and expected market sizes for our products. These expectations are subject to risks and uncertainties, and actual results may differ materially from those anticipated due to many factors, including competition, acce...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free